Predictors of response by risk factor (intention to treat analysis)
| SVR at 24 wks post-treatment | |||
|---|---|---|---|
| Placebo (n) | p Value | Amantadine (n) | |
| SVR, sustained viral response. | |||
| Overall | 27.9% (24/86) | 0.4 | 24.7% (21/85) |
| Cirrhotic | 13.6% (3/22) | 0.5 | 18.8% (3/16) |
| Non-cirrhotic | 32.8% (21/64) | 0.3 | 26.1% (18/69) |
| Viral load | |||
| <1 000 000 copies/ml | 30.6% (15/49) | 0.4 | 35.3% (18/51) |
| >1 000 000 copies/ml | 24.3% (9/37) | 0.08 | 8.8% (3/34) |
| Race | |||
| Caucasian | 31.9% (23/72) | 0.5 | 29.9% (20/67) |
| African-American | 0% (0/12) | N/A | 0% (0/17) |
| Others | 50% (1/2) | 0.7 | 100% (1/1) |
| Genotype | |||
| 1a/b | 18.3% (13/71) | 0.5 | 18.9% (14/74) |
| Other (2, 3) | 69.2% (9/13) | 0.6 | 66.7% (6/9) |
| Sex | |||
| Male | 28.3% (15/53) | 0.5 | 26.7% (12/45) |
| Female | 27.3% (9/33) | 0.4 | 22.5% (9/40) |
| Age | |||
| <50 y | 32.3% (21/65) | 0.4 | 28.6% (20/70) |
| >50 y | 14.3% (3/21) | 0.1 | 6.7% (1/15) |
| Weight | |||
| <75 kg | 27.3% (6/22) | 0.6 | 32.1% (9/28) |
| >75 kg | 28.1% (18/64) | 0.2 | 21.1% (12/57) |